This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Xenon Pharmaceuticals Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Parisa Karimi Tari: Innovator in Epilepsy Treatment
Introduction
Parisa Karimi Tari is a notable inventor based in Vancouver, Canada. She has made significant contributions to the field of medicine, particularly in the treatment of epilepsy. Her innovative approach has the potential to improve the lives of many individuals suffering from seizure disorders.
Latest Patents
Parisa holds a patent for a method of treating epilepsy. This patent, titled "Method for treating epilepsy," focuses on administering isolated fenfluramine enantiomers that are effective as anti-epilepsy drugs (AEDs). Despite having lower anti-seizure potency than fenfluramine racemate, these enantiomers are less cardiotoxic, making them a safer option for patients. The preferred embodiments of her invention contemplate the treatment of Dravet syndrome and other epileptic seizure disorders.
Career Highlights
Parisa is currently associated with Xenon Pharmaceuticals Inc., where she continues her research and development efforts. Her work is pivotal in advancing therapeutic options for epilepsy, showcasing her dedication to improving patient outcomes.
Collaborations
Some of her notable coworkers include Jeffrey Paul Bechard and Robin Sherrington, who contribute to her innovative projects and research initiatives.
Conclusion
Parisa Karimi Tari's contributions to epilepsy treatment through her patented methods highlight her role as a leading inventor in the medical field. Her work not only advances scientific knowledge but also offers hope to those affected by seizure disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile